EuMederis Pharmaceuticals, Inc. is focused on the design of novel, Best-in-Class peptide pharmaceuticals with improved bioavailability and efficacy in patients. These preclinical development candidates make use of our broadly-based, proprietary technology platform (EuPort) for the improvement of peptide drug action.
Initial products are directed at indications in pain, in control of osteoporosis, and in reversal of the inflammatory components of the metabolic syndrome.
Peptide hormones were among the earliest signals regulating multi-cellular organisms and play critical roles controling bodily functions from bacteria to yeast to man.
For example, peptide hormones from the intestine regulate all aspects of our interaction with food (hunger, satiety, motility) and control blood glucose levels (glucagon, GLP-1, GIP, etc.). While these roles are not yet completely understood, multiple important pharmaceuticals have resulted from early work in the area.
Similarly, peptide signals from fat cells (cytokines, chemokines, adipokines) regulate many of the actions that control energy storage and the inflammatory state related to diabetes.
In addition, peptide hormones from the brain coordinate "tone" in the body,modulating response to stress as well as many basic bodily functions (fluid and electrolyte balance, parturition, sexual cycles, growth, et al.
In short, research to generate peptide hormone analogs with much improved, marketable pharmaceutical action (drug-like) is a remarkably rich field for drug discovery.
EuMederis has carried out proof of concept studies in multiple areas that have "blockbuster" clinical potential and seeks investors as well as development partners for selected clinical candidates.
To find out more, please see the About Us and Research pages.